Prof Stephan Ehrmann is an expert in Critical care at Centre Hospitalier Universitaire de Tours (France). As of October 2026, ScienceLeadR ranks Stephan Ehrmann in the top 1% of experts worldwide for Pneumonia, Critical Illness and COVID-19. Stephan Ehrmann has authored 302 publications, the most recent in 2026, and is an investigator in 49 clinical trials, 5 of them ongoing. SLR score: 1,725 (community average: 125). How the SLR is computed.

LeadR Profile

1 725 ScienceLeadR Reputation 1725
Network Map

Critical care

Subspecialties: Pulmonology - Public Health - Hematology

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Organizations

Career arc: 2004 - 2026

Source: PubMed

Centre Hospitalier Universitaire de Tours

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 302

Citations

Citations: 11 514 1st author: 27 Last author: 47 Unique author: 2


Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Monitoring of Intensive Care Patients by a Physiology-Related GFR Method.
PMID 42802078 — physiology, iohexol, critical illness, plasma
J Appl Lab Med20260
Transfusion intensity in the ICU: Reasons and triggers.
PMID 42541477 — blood transfusion, hematology, hemorrhage, critical care, critical illness, intensive care units
Transfusion20260
Prone positioning in ARDS.
PMID 42474726 — lung, stress, physiological, critical care, intensive care units, prone position
Intensive Care Med20261
High-flow nasal cannula oxygen during breaks from noninvasive ventilation after extubation: an observational study.
PMID 42440109 — noninvasive ventilation, critical care, intensive care units, ventilation, cannula
Intensive Care Med20261
Impact of gender on how intensive care medicine residents experience their medical studies and training and perceive their specialty: a national survey.
PMID 42339190 — environment, sexual harassment
Ann Intensive Care20260

Clinical Studies 49

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 6 Study Director: 3

By phase:

N/A 32
Phase 3 11
Phase 1/Phase 2 2
Phase 2/Phase 3 2
Phase 2 1
Phase 4 1

By status:

Completed 33
Recruiting 6
Unknown 5
Terminated 2
Active not recruiting 1
Not yet recruiting 1
Withdrawn 1

By type:

Interventional 38
Observational 11

By Monocentric/Multicentric:

monocentric 14
multicentric2to4 10
multicentric5to9 3
multicentricup10 22

Main Topics

Cohort/Consortium Investigators 18

Ongoing Clinical Trials

5 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
Inhaled Amikacin Versus Placebo in Patients With Ventilator associated Tracheobronchitis
NCT07665788 — pneumonia, ventilator-associated, respiratory tract infections, pneumonia, critical illness, amikacin, cross infection, body weight, aminoglycosides, therapeutics, intensive care units, ventilation, random allocation, infections
Phase 3Not yet recruiting2026
CASPONEB Phase II safety lead in randomized blind placebo controlled clinical trial efficacy and safety of caspofungin aerosols for the curative treatment of Pneumocystis pneumonia in adjunction of conventional systemic antifungal therapy
2023-508861-34-00 — safety, aerosols, pneumocystis, caspofungin, pneumonia, therapeutics, pneumonia, pneumocystis
Phase 1/Phase 2Recruiting2025
Awake Prone Positioning of Patients Suffering Community Acquired Pneumonia Requiring Nasal High Flow Therapy
NCT06966310 — intubation, covid-19, pneumonia, therapeutics, prone position, community-acquired pneumonia
N/ARecruiting2025
Non inferiority of Continuing Oral Intake Versus Fasting in Patients With Acute Respiratory Failure
NCT06510972 — fasting, intubation, food, respiratory insufficiency, deglutition disorders, deglutition
N/ARecruiting2025
CaspoNEB Efficacy and Safety of Caspofungin Aerosols for the Curative Treatment of Pneumocystis Pneumonia
NCT06892951 — nurses, pneumocystis infections, pneumocystis carinii, lung, safety, saline solution, serum, powders, suspensions, pharmaceutical preparations, aerosols, pneumocystis, echinocandins, masks, acetates, inhalation, caspofungin, pneumonia, respiratory aspiration, outcome assessment, health care, therapeutics, lung diseases, ventilation, pneumonia, pneumocystis, infections, lung diseases, interstitial
Phase 1/Phase 2Recruiting2025

LeadR Networks

Main global connection map